These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 34949118)

  • 1. US health care utilization and costs in adult patients with atopic dermatitis by disease severity.
    Wang X; Boytsov NN; Gorritz M; Malatestinic WN; Goldblum OM; Wade RL
    J Manag Care Spec Pharm; 2022 Jan; 28(1):69-77. PubMed ID: 34949118
    [No Abstract]   [Full Text] [Related]  

  • 2. The direct and indirect costs of adult atopic dermatitis.
    Manjelievskaia J; Boytsov N; Brouillette MA; Onyekwere U; Pierce E; Goldblum O; Bonafede M
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1416-1425. PubMed ID: 34595952
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparing the burden of illness in patients with alopecia areata vs atopic dermatitis in the US population from a payer perspective.
    Fenske DC; Ding Y; Morrow P; Smith SG; Silver MK; Moynihan M; Manjelievskaia J
    J Manag Care Spec Pharm; 2023 Apr; 29(4):409-419. PubMed ID: 36989453
    [No Abstract]   [Full Text] [Related]  

  • 4. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States.
    Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
    J Manag Care Spec Pharm; 2022 Aug; 28(8):818-829. PubMed ID: 35876297
    [No Abstract]   [Full Text] [Related]  

  • 5. Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
    Foster SA; Zhu B; Guo J; Nikai E; Ojeh C; Malatestinic W; Goldblum O; Kornberg LJ; Wu JJ
    J Manag Care Spec Pharm; 2016 Apr; 22(4):396-405. PubMed ID: 27023693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Care Utilization and Direct Costs Among Patients Diagnosed with Cluster Headache in U.S. Health Care Claims Data.
    Choong CK; Ford JH; Nyhuis AW; Robinson RL; Aurora SK
    J Manag Care Spec Pharm; 2018 Sep; 24(9):921-928. PubMed ID: 30156448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs.
    Ford JH; Schroeder K; Nyhuis AW; Foster SA; Aurora SK
    J Manag Care Spec Pharm; 2019 Jan; 25(1):46-59. PubMed ID: 30044691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health Care Resource Utilization and Costs Among Adults with Atopic Dermatitis in the United States: A Claims-Based Analysis.
    Drucker AM; Qureshi AA; Amand C; Villeneuve S; Gadkari A; Chao J; Kuznik A; Bégo-Le-Bagousse G; Eckert L
    J Allergy Clin Immunol Pract; 2018; 6(4):1342-1348. PubMed ID: 29174063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Care Resource Utilization and Cost Before Initial Schizophrenia Diagnosis.
    Wallace A; Barron J; York W; Isenberg K; Franchino-Elder J; Sidovar M; Sand M
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1102-1110. PubMed ID: 31556820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with Idiopathic Membranous Nephropathy: A Real-World Clinical and Economic Analysis of U.S. Claims Data.
    Nazareth TA; Kariburyo F; Kirkemo A; Xie L; Pavlova-Wolf A; Bartels-Peculis L; Vaidya N; Sim JJ
    J Manag Care Spec Pharm; 2019 Sep; 25(9):1011-1020. PubMed ID: 31283419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis.
    Croteau SE; Cook K; Sheikh L; Chawla A; Sammon J; Solari P; Kim B; Hinds D; Thornburg CD
    J Manag Care Spec Pharm; 2021 Mar; 27(3):316-326. PubMed ID: 33645244
    [No Abstract]   [Full Text] [Related]  

  • 13. Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden.
    Huang SP; DerSarkissian M; Gu YM; Duh MS; Wang MJ; Benson J; Vu J; Averell C; Bell CF
    J Manag Care Spec Pharm; 2023 Apr; 29(4):365-377. PubMed ID: 36989451
    [No Abstract]   [Full Text] [Related]  

  • 14. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
    Mehta S; Ghosh S; Sander S; Kuti E; Mountford WK
    J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Burden of Illness in Adult Patients with Nocturia.
    Dmochowski R; Brucker BM; Cole E; Kawahara S; Pulicharam R; Burk C; Tung A; Hale D
    J Manag Care Spec Pharm; 2019 May; 25(5):593-604. PubMed ID: 30675816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Direct Cost of Managing a Rare Disease: Assessing Medical and Pharmacy Costs Associated with Duchenne Muscular Dystrophy in the United States.
    Thayer S; Bell C; McDonald CM
    J Manag Care Spec Pharm; 2017 Jun; 23(6):633-641. PubMed ID: 28530521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER).
    Ambrosini A; Estemalik E; Pascual J; Rettiganti M; Stroud C; Day K; Ford J
    J Manag Care Spec Pharm; 2022 Jun; 28(6):645-656. PubMed ID: 35451858
    [No Abstract]   [Full Text] [Related]  

  • 18. Incremental cost burden among patients with severe uncontrolled asthma in the United States.
    Burnette A; Wang Y; Rane PB; Chung Y; Princic N; Park J; Llanos JP; Lindsley AW; Ambrose CS
    J Manag Care Spec Pharm; 2023 Jul; 29(7):825-834. PubMed ID: 37404066
    [No Abstract]   [Full Text] [Related]  

  • 19. Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States.
    Lu M; Oladapo A; Wu Y; Farahbakhshian S; Ewenstein B
    J Manag Care Spec Pharm; 2021 Feb; 27(2):175-185. PubMed ID: 33307935
    [No Abstract]   [Full Text] [Related]  

  • 20. Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database.
    Folkerts K; Petruski-Ivleva N; Kelly A; Fried L; Blankenburg M; Gay A; Kovesdy CP
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1506-1516. PubMed ID: 33251992
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.